Cancer Targeted Technology
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Cancer Targeted Technology sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,751 sponsors by registered trial count).
Cancer Targeted Technology: 3 sponsored US clinical trials, none currently recruiting.
Cancer Targeted Technology sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 1 trials.
Upper-quartile sponsor footprint
Cancer Targeted Technology sits in the upper quartile of the sponsor corpus (#3,661 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
NCT03822871
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
NCT03427476
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
NCT02916537
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Therapeutic Areas
How the Cancer Targeted Technology early-phase archive is shaped
3 indexed studies, none listed as recruiting (0% open); 3 completed (100%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.